Curative effect of a course of monotherapy with rifampicin, isoniazid or streptomycin subsequent to combination treatment in murine tuberculosis.
D000284:Administration, Oral; D000818:Animals; D004359:Drug Therapy, Combination; D005260:Female; D005856:Germ-Free Life; D007279:Injections, Subcutaneous; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D008168:Lung / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D009163:Mycobacterium bovis / Q000302:isolation & purification; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D013307:Streptomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin